Abstract
There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC’s therapeutic agents that have shown the potential for progress in clinical practice. This review provides an overview of tyrosine kinase inhibitors targeting VEGF and KIT, BRAF and MEK inhibitors, TLR9 agonist, STAT3 inhibitors, and immune checkpoint blockers (PD1/PDL-1 inhibitors), for which recent advances have been reported. These new agents have the potential to provide benefits to CRC patients with unmet medical needs.
Funder
Italian Association for Cancer Research
Sapienza University of Rome
Institute Pasteur Italy
Subject
Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science
Reference190 articles.
1. World Cancer Research Fund, American Institute for Cancer Research
https://www.wcrf.org/dietandcancer/colorectal-cancer-statistics/
2. World Cancer Research Fund, American Institute for Cancer Research
https://www.wcrf.org/dietandcancer/worldwide-cancer-data/
3. Colorectal cancer: Epidemiology, risk factors, and protective factors
https://www.uptodate.com/contents/colorectal-cancer-epidemiology-risk-factors-and-protective-factors
4. GENETICS OF COLON CANCER: Impact of Inheritance on Colon Cancer Risk
5. Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: An updated review
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献